DKSH and Grünenthal Forge New Partnership in Asia-Pacific

DKSH Management Ltd. and Grünenthal have established a new partnership covering eight Asia-Pacific markets. This collaboration merges Grünenthal's expertise in pain management with DKSH Healthcare's comprehensive commercialization platform. The goal is to accelerate access to innovative pain therapies and support future growth in the region.

Under the agreement, DKSH will facilitate the launch of four key Grünenthal products—Qutenza®, Vimovo®, Palexia®, and Zomig®—in markets such as Hong Kong, Indonesia, and Singapore. This expansion builds on a successful past collaboration, highlighting a shared commitment to improve patient access to pain management solutions.

The partnership leverages DKSH's robust regional model, allowing seamless market execution while maintaining local market focus. By integrating capabilities such as regulatory affairs and supply chain management, the alliance aims to bring effective pain therapies to millions across Asia-Pacific.